CINECA IRIS Institutional Research Information System

BRINGHEN, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.851
EU - Europa 4.311
AS - Asia 3.374
SA - Sud America 432
OC - Oceania 134
AF - Africa 86
Continente sconosciuto - Info sul continente non disponibili 1
Totale 15.189
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.584
IT - Italia 1.406
CN - Cina 1.094
JP - Giappone 716
SG - Singapore 680
FR - Francia 389
SE - Svezia 374
DE - Germania 331
GB - Regno Unito 323
IE - Irlanda 289
BR - Brasile 270
IN - India 263
ES - Italia 223
CA - Canada 201
NL - Olanda 157
FI - Finlandia 133
AU - Australia 121
AT - Austria 118
VN - Vietnam 100
KR - Corea 96
UA - Ucraina 93
CH - Svizzera 87
HK - Hong Kong 78
PL - Polonia 67
TR - Turchia 66
ID - Indonesia 58
BE - Belgio 50
MX - Messico 49
CO - Colombia 47
PT - Portogallo 45
IL - Israele 44
GR - Grecia 43
RU - Federazione Russa 42
HU - Ungheria 28
TW - Taiwan 28
AR - Argentina 26
CL - Cile 26
PE - Perù 24
PK - Pakistan 23
DK - Danimarca 20
NO - Norvegia 20
TN - Tunisia 20
MN - Mongolia 17
UY - Uruguay 17
SN - Senegal 16
TH - Thailandia 16
MA - Marocco 15
CZ - Repubblica Ceca 14
RO - Romania 13
MY - Malesia 12
NZ - Nuova Zelanda 12
HR - Croazia 10
SA - Arabia Saudita 10
EC - Ecuador 9
KW - Kuwait 9
MK - Macedonia 9
ZA - Sudafrica 9
AE - Emirati Arabi Uniti 8
EG - Egitto 8
NG - Nigeria 8
QA - Qatar 8
TT - Trinidad e Tobago 7
BD - Bangladesh 6
UZ - Uzbekistan 6
BO - Bolivia 5
EE - Estonia 5
IQ - Iraq 5
KZ - Kazakistan 5
PH - Filippine 5
AM - Armenia 4
IR - Iran 4
MT - Malta 4
VE - Venezuela 4
AD - Andorra 3
BG - Bulgaria 3
CU - Cuba 3
DZ - Algeria 3
GF - Guiana Francese 3
JO - Giordania 3
KE - Kenya 3
SI - Slovenia 3
BN - Brunei Darussalam 2
KY - Cayman, isole 2
LU - Lussemburgo 2
MD - Moldavia 2
NP - Nepal 2
PA - Panama 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
CI - Costa d'Avorio 1
CR - Costa Rica 1
ET - Etiopia 1
EU - Europa 1
GE - Georgia 1
GH - Ghana 1
GL - Groenlandia 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
Totale 15.183
Salva come PNG Salva come JPEG
Città #
Fairfield 384
Singapore 353
Santa Clara 332
Chandler 330
Beijing 279
Dublin 273
Redwood City 263
Florence 250
Ashburn 248
Torino 236
Tokyo 200
Cambridge 186
Houston 175
Turin 157
Woodbridge 154
Wilmington 137
Seattle 134
Ann Arbor 129
Nyköping 127
Los Angeles 97
Vienna 91
Shanghai 86
Dearborn 84
New York 81
Medford 77
Ottawa 77
Columbus 76
Princeton 72
Chicago 69
Milan 66
Guangzhou 62
Pisa 61
Duncan 60
London 60
Villeurbanne 59
Hangzhou 56
Jakarta 53
Nanjing 52
Portland 52
Madrid 51
Paris 50
Minneapolis 49
Dong Ket 47
Boston 46
Indianapolis 45
San Diego 44
Helsinki 42
Rochester 41
Jacksonville 39
Rome 39
Seoul 37
Toronto 37
Warsaw 37
Philadelphia 36
Sydney 36
Osaka 35
Raritan 35
São Paulo 32
Baltimore 31
Hong Kong 30
Hyderabad 29
Norwalk 29
Brussels 28
Providence 28
San Jose 28
Amsterdam 27
Perth 27
Newbury Park 26
Atlanta 25
Silver Spring 25
Charlotte 24
Mumbai 24
Boardman 23
Kansas City 23
Athens 22
Barcelona 22
Chengdu 22
Düsseldorf 22
Munich 22
Saint Paul 21
San Mateo 21
Santiago 21
Wuhan 21
Bengaluru 19
Billings 19
Breda 19
Frankfurt am Main 19
Hebei 19
Lima 19
Nuremberg 19
San Francisco 19
St Louis 19
Brzeg 18
Fukuoka 18
Phoenix 18
Pittsburgh 18
Budapest 17
Flushing 17
Miami 17
Salt Lake City 17
Totale 7.448
Salva come PNG Salva come JPEG
Nome #
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 3.244
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) 1.347
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma 837
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 626
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group 462
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension 416
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma 369
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. 358
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma 347
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials 325
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications 322
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 300
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma 275
Determining treatment intensity in elderly patients with multiple myeloma 264
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma 241
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma 220
How is patient care for multiple myeloma advancing? 211
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study 202
Treatment of newly diagnosed elderly multiple myeloma 179
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. 171
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report 167
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, nordic and turkish myeloma study groups 167
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients 167
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies 165
Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis 164
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial 162
Emerging drugs and combinations to treat multiple myeloma 161
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing 160
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. 146
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. 144
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) 144
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma 137
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 134
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma 128
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma 127
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies 125
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials 124
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials 121
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients 111
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. 109
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score 109
Maintenance Treatment and Survival in Patients With Myeloma A Systematic Review and Network Meta-analysis 104
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network 103
Ultra-Low-Dose Whole-Body Computed Tomography Protocol Optimization for Patients With Plasma Cell Disorders: Diagnostic Accuracy and Effective Dose Analysis From a Reference Center 103
Multiple myeloma patients undergoing carfilzomib: Development and validation of a risk score for cardiovascular adverse events prediction 96
Monoclonal antibodies to treat multiple myeloma: A dream come true 91
Treatment of newly diagnosed elderly multiple myeloma 90
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma 77
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial 75
Systemic virotherapy for multiple myeloma 73
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma 71
Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy 70
Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant 70
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. 69
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. 65
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. 63
Approach to the Older Adult With Multiple Myeloma 63
New treatment strategies for elderly myeloma patients 63
The role of monoclonal antibodies in the first-line treatment of transplant-ineligible patients with newly diagnosed multiple myeloma 63
Melphalan and its role in the management of patients with multiple myeloma 61
Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study 61
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. 59
Risk of infection in patients with multiple myeloma treated with T-cell redirecting approaches: a call out for clinicians 56
Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma 49
Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience 40
Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study 40
Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment 38
Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor 29
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review 23
Blood pressure variability as predictor of cancer therapy-related cardiovascular toxicity in patients with Multiple Myeloma 14
M‐protein‐related necrobiotic granuloma in a multiple myeloma patient treated with daratumumab, lenalidomide and dexamethasone 11
Totale 15.578
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.574
article - articoli 0
book - libri 0
conference - conferenze 769
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.343
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202078 0 0 0 0 0 0 0 0 0 0 0 78
2020/20212.283 74 134 164 147 206 221 195 202 232 198 202 308
2021/20222.442 174 173 149 240 176 139 269 141 127 201 300 353
2022/20232.550 151 208 184 207 178 337 183 232 256 172 246 196
2023/20242.245 176 240 161 240 191 213 169 214 60 185 200 196
2024/20253.508 198 212 282 287 582 329 239 233 324 284 290 248
Totale 15.578